General Information

Name:	Dr. Dr. Anja Mottok
Date of Birth:	10.10.1978
Gender:	Female
Address:	Institute of Human Genetics, Ulm University Albert-Einstein-Allee 11, 89081 Ulm, Germany
Phone:	+49 731 500 65450
E-Mail:	anja.mottok@uni-ulm.de
Current Position:	Clinician-Scientist and Resident Physician

Academic Education

2014-2017	PhD studies, Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada
1997-2004	Medical Schools Würzburg and Frankfurt am Main

Academic Degrees

2017	Doctoral Thesis (PhD), Faculty of Medicine, University of British Columbia, Vancouver, Canada; Mentor: Dr. Christian Steidl, Thesis title: „Characterization of genomic alterations in *CIITA* and their functional and clinical implications in malignant lymphomas"
2005	Doctoral Thesis (MD), Department of Pathology, Faculty of Medicine, University of Frankfurt, Germany, Mentor: Prof. M.-L. Hansmann, Thesis title: „RNA-analyses on formalin-fixed, paraffin-embedded tissue and AID-expression in lymphocyte-predominant Hodgkin lymphoma" *(summa cum laude)*

Professional Experience

Since 2018	Clinician-Scientist and Resident Physician, Institute of Human Genetics, Ulm University
2017-2018	Consultant Physician and Head of the Cytogenetics Laboratory, Department of Pathology, University of Würzburg
2013-2017	Postdoctoral Fellow, Department for Lymphoid Cancer Research, BC Cancer Agency, Vancouver, BC, Canada
2013-2013	Consultant Physician, Department of Pathology, University of Würzburg
2008-2013	Resident Physician, Department of Pathology, University of Würzburg
2005-2008	Resident Physician, Senckenberg Institute of Pathology, University Hospital Frankfurt am Main
2004-2005	Resident Physician, Department of Internal Medicine, Städtische Kliniken, Frankfurt-Höchst

Miscellaneous

Awards, Honors, Positions:

2017	Translational Research Training in Hematology (TRTH) program, ASH/EHA
2016	Abstract Achievement Award 2nd ASH Meeting on Lymphoma Biology
2015	Abstract Achievement Award 57th ASH Annual Meeting, Orlando
2015	Canadian Cancer Society Research Institute Travel Award, 57th ASH Annual Meeting
2015	Travel Award, Cancer Genomics 2015 workshop (Ontario Institute for Cancer Research, Toronto)
2015	Travel Award, 6th Annual Meeting of the Terry Fox Research Institute
2014	Faculty of Medicine Graduate Award, UBC, Vancouver, Canada

2014-2017	International Tuition Award, UBC, Vancouver, Canada

Grants and fellowships:

2018-2020	**Clinician-Scientist Program, Faculty of Medicine, University of Ulm**
2017-2019	**"Deciphering the cellular crosstalk in the tumor microenvironment of classical Hodgkin lymphoma"** Canadian Cancer Society Research Institute - Innovation Grant, Co-author, Amount: 196.000 CAD
2016-2018	Lymphoma Canada, Research Fellowship Award, Amount: 105.000 CAD
2015-2017	Michael Smith Foundation for Health Research, Post-Doctoral Fellowship Award, Amount: 59.000 CAD
2013-2015	Postdoctoral Fellowship Award, Mildred-Scheel Cancer Foundation, Amount: 76.026 €
2012-2013	„Evaluation of YB-1, c-MYC and RAS as prognostic markers in multiple myeloma“ (cooperation with the Dept. of Internal Medicine II, University Hospital Würzburg), IZKF JMU Würzburg, Amount: 154.000 €
2010-2013	„Characterization of the regulation and function of CD56 expression in multiple myeloma“, Deutsche Krebshilfe, Co-applicant, Amount: 344.400 €

Publications

1. Ennishi D, Takata K, Béguelin W, Duns G, Mottok A, Farinha P, Bashashati A, Saberi S, Boyle M, Meissner B, Ben-Neriah S, Woolcock BW, Telenius A, Lai D, Teater M, Kridel R, Savage KJ, Sehn LH, Morin RD, Marra MA, Shah SP, Connors JM, Gascoyne RD, Scott DW, Melnick AM, Steidl C. Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition. **Cancer Discov**. 2019;9(4):546-63.
2. Ennishi D, Jiang A, Boyle M, Collinge B, Grande BM, Ben-Neriah S, Rushton C, Tang J, Thomas N, Slack GW, Farinha P, Takata K, Miyata-Takata T, Craig J, Mottok A, Meissner B, Saberi S, Bashashati A, Villa D, Savage KJ, Sehn LH, Kridel R, Mungall AJ, Marra MA, Shah SP, Steidl C, Connors JM, Gascoyne RD, Morin RD, Scott DW. Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma. **J Clin Oncol**. 2019;37(3):190-201.
3. Arthur SE, Jiang A, Grande BM, Alcaide M, Cojocaru R, Rushton CK, Mottok A, Hilton LK, Lat PK, Zhao EY, Culibrk L, Ennishi D, Jessa S, Chong L, Thomas N, Pararajalingam P, Meissner B, Boyle M, Davidson J, Bushell KR, Lai D, Farinha P, Slack GW, Morin GB, Shah S, Sen D, Jones SJM, Mungall AJ, Gascoyne RD, Audas TE, Unrau P, Marra MA, Connors JM, Steidl C, Scott DW, Morin RD. Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma. **Nat Commun**. 2018;9(1):4001.
4. Mottok A, Wright G, Rosenwald A, Ott G, Ramsower C, Campo E, Braziel RM, Delabie J, Weisenburger DD, Song JY, Chan WC, Cook JR, Fu K, Greiner T, Smeland E, Holte H, Savage KJ, Glinsmann-Gibson BJ, Gascoyne RD, Staudt LM, Jaffe ES, Connors JM, Scott DW, Steidl C, Rimsza LM. Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. **Blood**. 2018;132(22):2401-05.
5. Mottok A, Jurinovic V, Farinha P, Rosenwald A, Leich E, Ott G, Horn H, Klapper W, Boesl M, Hiddemann W, Steidl C, Connors JM, Sehn LH, Gascoyne RD, Hoster E, Weigert O, Kridel R. FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab-containing regimens. **Blood**. 2018;131(2):226-35.
6. Chan FC*, Mottok A*, Gerrie AS, Power M, Nijland M, Diepstra A, van den Berg A, Kamper P, d'Amore F, d'Amore AL, Hamilton-Dutoit S, Savage KJ, Shah SP, Connors JM, Gascoyne RD, Scott DW, Steidl C. Prognostic model to predict post-autologous stem-cell transplantation outcomes in classical Hodgkin lymphoma. **J Clin Oncol**. 2017;35(32):3722-33. *Equal contribution
7. Kridel R, Chan FC, Mottok A, Boyle M, Farinha P, Tan K, Meissner B, Bashashati A, McPherson A, Roth A, Shumansky K, Yap D, Ben-Neriah S, Rosner J, Smith MA, Nielsen C, Giné E, Telenius A, Ennishi D, Mungall A, Moore R, Morin RD, Johnson NA, Sehn LH, Tousseyn T, Dogan A, Connors JM, Scott DW, Steidl C, Marra MA, Gascoyne RD, Shah SP. Histological transformation and progression in follicular lymphoma: A clonal evolution study. **PLoS Med**. 2016;13(12):e1002197.

8. Boice M, Salloum D, Mourcin F, Sanghvi V, Amin R, Oricchio E, Jiang M, Mottok A, Denis-Lagache N, Ciriello G, Tam W, Teruya-Feldstein J, de Stanchina E, Chan WC, Malek SN, Ennishi D, Brentjens RJ, Gascoyne RD, Cogné M, Tarte K, Wendel HG. Loss of the HVEM tumor suppressor in lymphoma and restoration by modified CAR-T cells. **Cell**. 2016;167(2):405-18.
9. Mottok A, Woolcock B, Chan FC, Tong KM, Chong L, Farinha P, Telenius A, Chavez E, Ramchandani S, Drake M, Boyle M, Ben-Neriah S, Scott DW, Rimsza LM, Siebert R, Gascoyne RD, Steidl C. Genomic alterations in CIITA are frequent in primary mediastinal large B cell lymphoma and are associated with diminished MHC class II expression. **Cell Rep**. 2015;13(7):1418-31.
10. Scott DW*, Mottok A*, Ennishi D, Wright GW, Farinha P, Ben-Neriah S, Kridel R, Barry GS, Hother C, Abrisqueta P, Boyle M, Meissner B, Telenius A, Savage KJ, Sehn LH, Slack GW, Steidl C, Staudt LM, Connors JM, Rimsza LM, Gascoyne RD. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. **J Clin Oncol**. 2015;33(26):2848-56. *Equal contribution